Figure 1
Survival estimate from diagnosis of PMF patients according to COMFORT-2 (n=76) and DIPSS cohort (N=111). Numbers above the COMFORT-2 curve represent the number of patients entering ruxolitinib treatment at each time point during follow-up.
Survival estimate from diagnosis of PMF patients according to COMFORT-2 (n=76) and DIPSS cohort (N=111). Numbers above the COMFORT-2 curve represent the number of patients entering ruxolitinib treatment at each time point during follow-up.
